ADMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADMA Biologics Inc is not a strong buy for a beginner investor with a long-term strategy at this time. The stock faces significant legal challenges, mixed analyst sentiment, and lacks strong technical or proprietary trading signals. While hedge funds are buying, the overall sentiment and risks outweigh potential gains for a long-term, beginner investor.
The MACD is positive but contracting, RSI is neutral at 50.288, and moving averages are converging. The stock is trading near its pivot level of 8.357, with resistance at 8.745 and support at 7.97. No clear bullish or bearish trend is evident.
Hedge funds are significantly increasing their positions, with a 719.51% increase in buying over the last quarter.
Multiple class action lawsuits alleging misleading statements and financial irregularities. Concerns about channel stuffing and revenue recognition issues. Downgrades and reduced price targets from analysts. Insider trading is neutral with no significant activity.
No financial data available for analysis due to an error in the provided dataset.
Analysts have mixed views. Mizuho and Canaccord maintain positive ratings but have lowered price targets due to weaker-than-expected performance and guidance. Cantor Fitzgerald downgraded the stock to Neutral, citing lack of clarity and concerns about financial practices.
